Bioventus (NASDAQ:BVS) Sets New 12-Month High - Here's What Happened

Key Points

• Bioventus shares reached a new 52-week high of $13.85, up 5.1% from the prior close, with a market capitalization of approximately $1.16 billion.
• Analysts maintain a favorable outlook, with an average rating of “Buy” and a consensus price target of $14.75. Recent targets include $15.00 from Canaccord Genuity and $14.00 from Barrington Research.
• Bioventus exceeded quarterly earnings expectations, reporting $0.15 EPS versus the $0.09 consensus, and institutional investors own nearly 63% of the company’s shares.

Bioventus Inc. (NASDAQ:BVS - Get Free Report)'s share price reached a new 52-week high during trading on Monday . The stock traded as high as $13.85 and last traded at $13.8360, with a volume of 54574 shares changing hands. The stock had previously closed at $13.17.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BVS. Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 price target on shares of Bioventus in a research note on Tuesday, June 16th. Barrington Research restated an "outperform" rating and issued a $14.00 price target on shares of Bioventus in a report on Tuesday, June 30th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Bioventus in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $14.75.

Bioventus Stock Up 5.1%

The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 33.70, a PEG ratio of 1.68 and a beta of 0.63. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The stock has a fifty day moving average of $10.30 and a two-hundred day moving average of $9.48.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, analysts predict that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

A number of institutional investors and hedge funds have recently bought and sold shares of BVS. Engine Capital Management LP acquired a new position in Bioventus during the first quarter valued at approximately $2,876,000. Hillsdale Investment Management Inc. grew its stake in Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company's stock worth $6,128,000 after buying an additional 401,230 shares during the period. Fifth Third Bancorp acquired a new stake in shares of Bioventus in the first quarter worth $1,478,000. Wesbanco Bank Inc. acquired a new stake in shares of Bioventus in the first quarter worth $895,000. Finally, Legato Capital Management LLC raised its stake in shares of Bioventus by 1,042.8% in the 4th quarter. Legato Capital Management LLC now owns 137,562 shares of the company's stock valued at $1,023,000 after acquiring an additional 125,525 shares during the period. Institutional investors and hedge funds own 62.94% of the company's stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.